The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...
A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy tissue. "This story goes back nearly 20 years," says Prof. Paul François. This ...
Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...
A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...
Luke Pase and Prof. Fujiwara discuss how new targeting strategies and scalable manufacturing approaches are advancing ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
St. David's South Austin enrolled the first patient in a global lymphoma therapy study using a next-generation CAR T approach ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results